Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
出版年份 2021 全文链接
标题
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
作者
关键词
-
出版物
EMBO Molecular Medicine
Volume -, Issue -, Pages -
出版商
EMBO
发表日期
2021-03-12
DOI
10.15252/emmm.202013366
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- CSI NGS Portal: An Online Platform for Automated NGS Data Analysis and Sharing
- (2020) Omer An et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
- (2020) Nathalie Percie du Sert et al. PLOS BIOLOGY
- Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
- (2020) Michelle McMullen et al. Cancers
- Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma
- (2020) Mariam Gachechiladze et al. LUNG CANCER
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Non-enzymatic roles of human RAD51 at stalled replication forks
- (2019) Jennifer M. Mason et al. Nature Communications
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
- (2018) Willi Sauerbrei et al. JNCI-Journal of the National Cancer Institute
- Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy
- (2018) Euan A. Stronach et al. MOLECULAR CANCER RESEARCH
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
- (2018) Willi Sauerbrei et al. JNCI-Journal of the National Cancer Institute
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
- (2018) Marta Castroviejo‐Bermejo et al. EMBO Molecular Medicine
- DNA repair defects and implications for immunotherapy
- (2018) Katherine M. Bever et al. JOURNAL OF CLINICAL INVESTIGATION
- RAD51 interconnects between DNA replication, DNA repair and immunity
- (2017) Souparno Bhattacharya et al. NUCLEIC ACIDS RESEARCH
- Replication fork reversal triggers fork degradation in BRCA2-defective cells
- (2017) Sofija Mijic et al. Nature Communications
- Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein
- (2016) Alaa Tarig Alshareeda et al. BREAST CANCER RESEARCH AND TREATMENT
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks
- (2016) Martin Fischer et al. NUCLEIC ACIDS RESEARCH
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype
- (2015) Tuan Zea Tan et al. Oncotarget
- Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
- (2014) K. A. T. Naipal et al. CLINICAL CANCER RESEARCH
- “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
- (2014) Alison Davis et al. GYNECOLOGIC ONCOLOGY
- Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
- (2014) Monique D. Topp et al. Molecular Oncology
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
- (2012) S. Banerjee et al. ANNALS OF ONCOLOGY
- RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma
- (2012) Pierre Tennstedt et al. INTERNATIONAL JOURNAL OF CANCER
- Primary culture and immortalization of human fallopian tube secretory epithelial cells
- (2012) Alison M Karst et al. Nature Protocols
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- (2010) M. Graeser et al. CLINICAL CANCER RESEARCH
- Overexpression of RAD51 occurs in aggressive prostatic cancer
- (2009) Anita Mitra et al. HISTOPATHOLOGY
- A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
- (2008) T. Bonome et al. CANCER RESEARCH
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
- (2008) R. W. Tothill et al. CLINICAL CANCER RESEARCH
- “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations
- (2008) David S.P. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started